AstraZeneca PLC AZN

Morningstar Rating
GBX12,304.00 −60.00 (0.49%)
View Full Chart

Company Report

Price vs Fair Value

AZN is trading at a LOCK|r@m<JcV premium.
Price
GBX12,364.00
Fair Value
LOCK|Z^<v
Uncertainty
LOCK|&zzD
1-Star Price
LOCK|Jt%R
5-Star Price
LOCK|><
Economic Moat
LOCK|gV
Capital Allocation
LOCK|k#<Drf@

Bulls Say, Bears Say

Bulls

The company has a healthy oncology portfolio, including Tagrisso, Imfinzi, Calquence, Enhertu, and Truqap, which looks well positioned to drive major cash flows over the next decade.

Bears

The company's strong entrenchment in respiratory disease could cause challenges, as pricing power in this market tends to be weak.

News

Trading Information

Previous Close Price
GBX12,364.00
Day Range
GBX12,266.0012,578.00
52-Week Range
GBX9,892.0015,732.00
Bid/Ask
GBX12,400.00 / GBX12,778.00
Shares Outstanding
1.55B
Market Cap
GBX19.08T
Volume/Avg
2M / 2M

Key Statistics

Price/Earnings (Normalized)
17.94
Price/Sales
4.28
Dividend Yield (Trailing)
1.91%
Dividend Yield (Forward)
1.91%
Total Yield
1.91%

Company Profile

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
96,100

Competitors

Valuation

Metric
AZN
BMY
NVS
Price/Earnings (Normalized)
17.949.6417.30
Price/Book Value
5.345.797.45
Price/Sales
4.282.405.15
Price/Cash Flow
16.247.8914.75
Price/Earnings
AZN
BMY
NVS

Financial Strength

Metric
AZN
BMY
NVS
Quick Ratio
0.701.180.53
Current Ratio
0.911.420.85
Interest Coverage
8.176.3113.66
Quick Ratio
AZN
BMY
NVS

Profitability

Metric
AZN
BMY
NVS
Return on Assets (Normalized)
9.16%13.15%15.46%
Return on Equity (Normalized)
22.59%65.90%39.95%
Return on Invested Capital (Normalized)
14.71%19.89%22.43%
Return on Assets
AZN
BMY
NVS

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|&><Rm<gFLOCK|tcZ$1T
Johnson & Johnson
JNJ
LOCK|%kw<GKGLOCK|nz!$611B
AbbVie Inc
ABBV
LOCK|@@sp&X<LOCK|G$&$432B
Roche Holding AG ADR
RHHBY
LOCK|Lbv#wrRLOCK|t%y$320B
Merck & Co Inc
MRK
LOCK|RW%tVQtLOCK|wh#$298B
Novartis AG ADR
NVS
LOCK|dtJ?&H@LLOCK|j?$$287B
AstraZeneca PLC
AZN
LOCK|<ry<V^!LOCK|%xY$256B
Novo Nordisk AS ADR
NVO
LOCK|NSLLkr>XLOCK|%!t$215B
Amgen Inc
AMGN
LOCK|>yKM%W>>LOCK|?K$192B
Gilead Sciences Inc
GILD
LOCK|xptJVsyLOCK|K%$161B

Sponsor Center